Venus Remedies Ltd secures Renewal of Prestigious DSIR in-house R&D Recognition

Venus Remedies Limited has secured renewal of in-house Research & Development recognition from the Department of Scientific and Industrial Research (DSIR), Government of India, for its R&D unit, Venus Medicine Research Centre OVMRC).

DSIR recognition is granted to organisations that operate a dedicated in-house R&D unit with defined research objectives, qualified scientific staff, and separately accounted R&D expenditure. The renewal confirms that VMRC continues to meet these conditions.

The recognition supports VMRC's ongoing work in antimicrobial resistance, including the development of VRP-034, a novel polymyxin 8 formulation that holds USFDA Qualified Infectious Disease Product (QIDP) designation, and the GASAR resistance surveillance study.

Shares of Venus Remedies Limited was last trading in BSE at Rs. 1637.10 as compared to the previous close of Rs. 1559.15. The total number of shares traded during the day was 63944 in over 1381 trades.

The stock hit an intraday high of Rs. 1637.10 and intraday low of 1559.15. The net turnover during the day was Rs. 104201791.00.

Source : Equity Bulls

Keywords

VenusRemedies INE411B01019 Pharmaceuticals Renewal DSIR RandDRecognition